Haloperidol-induced changes in glutathione and energy metabolism: Effect of nicergoline.

European Journal of Pharmacology

Volumn 367, Issue 1, 1999, Pages 67-72

  Vairetti, Mariapia ^a   Feletti, Fausto ^a   Battaglia, Angelo ^b   Pamparana, Franco ^b   Canonico, Pier Luigi ^a   Richelmi, Plinio ^a   Bertè, Francantonio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b PFIZER INC   (United States)

Author keywords

Free radical; Haloperidol; Neuroleptic; Nicergoline; Tardive dyskinesia

Indexed keywords

ADENOSINE TRIPHOSPHATE; ERGOT DERIVATIVE; GLUTATHIONE; HALOPERIDOL; NEUROLEPTIC AGENT; NICERGOLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; LIVER; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0032966492     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00925-X     Document Type: Article

References (30)

1. Adler L.A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal B.A., Angrist B. Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry. 150:1993;1405-1407.
2. Battaglia A., Bruni G., Ardia A., Sacchetti G. Nicergoline in mild to moderate dementia. A multicenter, double-blind, placebo-controlled study. J. Am. Geriatr. Soc. 37:1989;295-302.
3. Benzi G., Manzo L., De Bernardi M., Ferrara A., Sanguinetti L., Arrigoni E., Bertè F. Action of lysergide, ephedrine and nicergoline on brain metabolizing activity. J. Pharmacol. Sci. 60:1971;1320-1324.
4. Bird, E.D., Collins, G.H., Dodson, M.H., Grant, L.H., 1967. The effect of phenothiazine on the manganese concentration in the basal ganglia of sub-human primates. In: Barbeau, A., Burnette, J.-R. (Eds.), Progress in Neurogenetics. Excerpta Medica, Montreal/Amsterdam, pp. 600-605.
5. Cadet J.L., Lohr J.B., Jeste D.V. Free radicals and tardive dyskinesia. Trends Neurosci. 9:1986;107-108.
6. Cadet, J.L., Lohr, J.B., Jeste, D.V., 1987. Tardive dyskinesia and schizophrenic burnout: the possible involvement of cytotoxic free radicals. In: Henn, F.A., DeLisi, L.E. (Eds.), Handbook of Schizophrenia: The Neurochemistry and Pharmacology of Schizophrenia. Elsevier, Amsterdam, pp. 425-438.
7. Canonico P.L., Sortino M.A., Carfagna N., Cavallaro S., Pamparana F., Annoni K., Wong E., Post C. Pharmacological basis for the clinical effects of nicergoline in dementia. Geriatria. 5:1996;24-49.
8. Carfagna N., Di Clemente A., Cavanus S., Damiani D., Gerna M., Salmoiraghi P., Cattaneo B., Post C. Modulation of hippocampal Ach release by chronic nicergoline treatment in freely moving young and aged rats. Neurosci. Lett. 197:1995;195-198.
9. Cohen, G., Spina, M.B., 1988. Hydrogen peroxide production in neurons: Implications for understanding Parkinson's disease. In: Hefti, F., Weiner, W.J. (Eds.), Progress in Parkinson Research. Plenum, New York, pp. 119-126.
10. Cohen B.M., Zubenko G.S. In vivo effects of psychotropic agents on the physical properties of cell membranes in the rat brain. Psychopharmacology. 86:1985;365-368.
11. Creese G., Burt D., Snyder S.H. Dopamine receptor binding and pharmacological potencies and antischizophrenic drugs. Science. 192:1976;481-483.
12. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., Waytt R.T. Treatment of tardive dyskinesia with vitamin E. Am J. Psychiatry. 149:1992;773-777.
13. Goldstein S.R., Matsumoto R.R., Thompson T.L., Patrick R.L., Bowen W.D., Walker J.M. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse. 4:1989;254-258.
14. Jones D.P. Determination of pyridine dinucleotides in cell extracts by high-performance liquid chromatography. J. Chromatogr. 225:1981;446-449.
15. Koren-Schwartzer N., Chen-Zion M., Ben-Porat H., Beitner R. Serotonin-induced decrease in brain ATP, stimulation of brain anaerobic glycolysis and elevation of plasma hemoglobin; the protective action of calmodulin antagonists. Gen. Pharmacol. 25:1994;1257-1262.
16. Lowry H.O., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 53:1951;265-275.
17. Matsuoka Y., Fukushima T., Iwata H., Mitsumoto M., Shibutani Y., Kawashima K., Kudo Y., Yshida R. Inhibitory action of nicergoline and its metabolites on acetylcholinesterase activity in the rat and mouse brain. Adv. Behav. Biol. 38B:1990;415-419.
18. Moretti, A., Carfagna, N., Caccia, C., Carpantieri, M., Amico, A., Marchi, G., Trunzo, F., 1985. Neurochemical effects of ergoline derivatives. In: Heidrich, H. (Ed.), Proof of Therapeutical Effectiveness of Nootropic and Vasoactive Drugs. Springer-Verlag, Berlin, pp 103-110.
19. Moretti A., Carfagna N., Caccia C., Carpantieri M. Effects of ergolines on neurotransmitter system in the rat brain. Arch. Int. Pharmacodyn. 294:1988;33-45.
20. Nielsen E.B., Lyon M. Evidence for cell loss in corpus striatum after long-term treatment with a neuroleptic drug (flupenthixol) in rats. Psychopharmacology. 59:1978;85-89.
21. Ogawa N., Asanuma M., Hirata H., Kondo Y., Kawada Y., Mori A. Cholinergic deficits in aged rat brain are corrected with nicergoline. Arch. Gerontol. Geriatr. 16:1993;103-110.
22. Ravindranath V., Reed D.J. Glutathione depletion and formation of glutathione protein mixed disulfide following exposure of brain mitochondria to oxidative stress. Biochem. Biophys. Res. Commun. 169:1990;150-158.
23. Reed D.J., Babson J.R., Beatty P.W., Brodie A.E., Ellis W.W., Potter D.W. High-performance liquid chromatography analysis of nanomole levels of glutathione, glutathione disulfide, and related thiols and disulfides. Anal. Biochem. 106:1980;55-62.
24. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J. Neurochem. 71:1998;1002-1012.
25. Saletu B., Paulus E., Lizmayer L., Anderer P., Semlitsch H.V., Grun-Berger J., Wicke L., Neuhold A., Podreka I. Nicergoline in senile dementia of Alzheimer type and multiinfarct dementia: a double-blind, placebo controlled, clinical and EEG/ERP mapping study. Psychopharmacology. 117:1995;385-395.
26. Shintomi K., Egou H., Tanaka T., Itakura T., Yoshimoto K., Matsumoto M., Matsuoka Y. Pharmacological study of nicergoline (I): protective effect against anoxic brain damages in animals. Folia Pharmacol. Jpn. 87:1986;427-434.
27. Shintomi K., Itakura T., Yoshimoto K., Ogawa Y., Fukushima T., Matsuoka Y. Pharmacological study of nicergoline (II): protective effect against anoxic brain damages in animals. Folia Pharmacol. Jpn. 87:1986;435-445.
28. Shivakumar B.R., Ravindranath V. Oxidative stress and thiol modification induced by chronic administration of haloperidol. J. Pharm. Exp. Ther. 265:1993;1137-1141.
29. Walker J.M., Hunter W.S. Role of sigma receptors in motor and limbic system function. Neuropsychopharmacology. 10:1994;837S.
30. Weiner, W.J., Nausieda, P.A., Klawans, H.L., 1980. Regional brain manganese levels in an animal model of tardive dyskinesia. In: Fann, W.E, Smith, R.C., Davis, J.M., Domino, E.F. (Eds.), Tardive Dyskinesia: Research and Treatment. SP Medical and Science Books, New York, pp. 159-163.